Extended indication Myocardial Infarction
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance Valsartan / sacubitril
Domain Cardiovascular diseases
Reason of inclusion Indication extension
Main indication Other medication for cardiovascular diseases
Extended indication Myocardial Infarction
Proprietary name Entresto
Manufacturer Novartis
Mechanism of action Combination therapy
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Entresto vertoont het werkingsmechanisme van een angiotensinereceptor-neprilysine-remmer door tegelijk neprilysine (neutrale endopeptidase, NEP) te remmen via LBQ657, de werkzame metaboliet van de prodrug sacubitril, en door de angiotensine II type 1-receptor (AT1-receptor) te blokkeren via valsartan.

Registration

Registration route Centralised (EMA)
Expected Registration 2021
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
Frequency of administration 2 times a day

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost 1,800.00
References Medicijnkosten.nl
Additional remarks € 2,49 per tablet. Voor behandeling op jaarbasis: €1.815,95.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Verwachte registratie HFpEF :2020, verwachte registratie MI: 2021.
References Fabrikant (nov 2017)

Other information

There is currently no futher information available.